Li 2016a.

Methods	Study design: Randomised clinical trial Study duration: April 2014 to April 2015 Duration of follow‐up: Not reported Setting: Hospital
Participants	Age (mean ± SD, range): TACE + RFA: 46.38 ± 11.54 years, 35‐81 years; TACE alone: 46.56 ± 11.48 years, 36‐81 years Male (n/total): TACE + RFA: 28/43; TACE alone: 29/42 Child‐Pugh Class (patients): Class A: TACE + RFA: 18; TACE: 19 Class B: TACE + RFA: 15; TACE: 16 Class C: TACE + RFA: 10; TACE: 7
Interventions	TACE + RFA group (n = 43): TACE: Chemotherapeutic drugs: mitomycin 15 mg and hydroxy camptothecin 15 mg/m2 RFA: The interval between TACE and RFA was 3‐5 weeks. TACE group (n = 42): Chemotherapeutic drugs: mitomycin 15 mg and hydroxy camptothecin 15 mg/m2
Outcomes	Serum level of AFP Liver function Tumour diameter Adverse events Recurrence rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.